Physiological and pathophysiological role of endocrine fibroblast growth factors

[1] Beenken A, Mohammadi M. The FGF family: Biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 2009; 8: 235–253. BeenkenA MohammadiM The FGF family: Biology, pathophysiology and therapy Nat. Rev. Drug Discov. 2009 8 235 253 10.1038/nrd2792368405419247306 Search in Google Scholar

[2] Danopoulos S, Schlieve CR, Grikscheit TC, Alam DA. Fibroblast growth factors in the gastrointestinal tract: Twists and turns. Dev. Dyn. 2017; 246: 344–352. DanopoulosS SchlieveCR GrikscheitTC AlamDA Fibroblast growth factors in the gastrointestinal tract: Twists and turns Dev. Dyn. 2017 246 344 352 10.1002/dvdy.2449128198118 Search in Google Scholar

[3] Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M, Ni Z, Zhang B, Zhang D, Luo F, et al. FGF/FGFR signaling in health and disease. Signal Transduct. Target Ther. 2020; 5: 181. XieY SuN YangJ TanQ HuangS JinM NiZ ZhangB ZhangD LuoF FGF/FGFR signaling in health and disease Signal Transduct. Target Ther. 2020 5 181 10.1038/s41392-020-00222-7746816132879300 Search in Google Scholar

[4] Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 2015; 4: 215–266. OrnitzDM ItohN The fibroblast growth factor signaling pathway Wiley Interdiscip. Rev. Dev. Biol. 2015 4 215 266 10.1002/wdev.176439335825772309 Search in Google Scholar

[5] Degirolamo C, Sabbà C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 2016; 15: 51–69. DegirolamoC SabbàC MoschettaA Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23 Nat. Rev. Drug Discov. 2016 15 51 69 10.1038/nrd.2015.926567701 Search in Google Scholar

[6] Nishimura T, Utsunomiya Y, Hoshikawa M, Ohuchi H, Itoh N. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochem. Biophys. Acta. 1999; 1444: 148–151. NishimuraT UtsunomiyaY HoshikawaM OhuchiH ItohN Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain Biochem. Biophys. Acta. 1999 1444 148 151 10.1016/S0167-4781(98)00255-39931477 Search in Google Scholar

[7] Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001; 2: reviews3005.1. OrnitzDM ItohN Fibroblast growth factors Genome Biol. 2001 2 reviews3005.1. 10.1016/B0-12-370879-6/00155-1 Search in Google Scholar

[8] Vergnes L, Lee JM, Chin RG, Auwerx J, Reue K. Diet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levels. Cell Metab. 2013; 17: 916–928. VergnesL LeeJM ChinRG AuwerxJ ReueK Diet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levels Cell Metab. 2013 17 916 928 10.1016/j.cmet.2013.04.007395644323747249 Search in Google Scholar

[9] Lee JM, Ong JR, Vergnes L, de Aguiar Vallim TQ, Nolan J, Cantor RM, Walters JR, Reue K. Diet1, bile acid diarrhea, and FGF15/19: Mouse model and human genetic variants. J. Lipid. Res. 2018; 59: 429–438. LeeJM OngJR VergnesL de Aguiar VallimTQ NolanJ CantorRM WaltersJR ReueK Diet1, bile acid diarrhea, and FGF15/19: Mouse model and human genetic variants J. Lipid. Res. 2018 59 429 438 10.1194/jlr.M078279583292429295820 Search in Google Scholar

[10] Babaknejad N, Nayeri H, Hemmati R, Bahrami S, Esmaillzadeh A. An overview of FGF19 and FGF21: The therapeutic role in the treatment of the metabolic disorders and obesity. Horm. Metab. Res. 2018; 50: 441–452. BabaknejadN NayeriH HemmatiR BahramiS EsmaillzadehA An overview of FGF19 and FGF21: The therapeutic role in the treatment of the metabolic disorders and obesity Horm. Metab. Res. 2018 50 441 452 10.1055/a-0623-290929883971 Search in Google Scholar

[11] Miyata M, Hata T, Yamazoe Y, Yoshinari K. SREBP-2 negatively regulates FXR-dependent transcription of FGF19 in human intestinal cells. Biochem. Biophys. Res. Commun. 2014; 443: 477–482. MiyataM HataT YamazoeY YoshinariK SREBP-2 negatively regulates FXR-dependent transcription of FGF19 in human intestinal cells Biochem. Biophys. Res. Commun. 2014 443 477 482 10.1016/j.bbrc.2013.11.12624321096 Search in Google Scholar

[12] So SSY, Yeung CHC, Schooling CM, El-Nezami H. Targeting bile acid metabolism in obesity reduction: A systematic review and meta-analysis. Obes. Rev. 2020; 21: e13017. SoSSY YeungCHC SchoolingCM El-NezamiH Targeting bile acid metabolism in obesity reduction: A systematic review and meta-analysis Obes. Rev. 2020 21 e13017 10.1111/obr.1301732187830 Search in Google Scholar

[13] Zhang F, Yu L, Lin X, Cheng P, He L, Li X, Lu X, Tan Y, Yang H, Cai L, Zhang C. Minireview: Roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases. Mol. Endocrinol. 2015; 29: 1400–1413. ZhangF YuL LinX ChengP HeL LiX LuX TanY YangH CaiL ZhangC Minireview: Roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases Mol. Endocrinol. 2015 29 1400 1413 10.1210/me.2015-1155458873026308386 Search in Google Scholar

[14] Kir S, Kliewer SA, Mangelsdorf DJ. Roles of FGF19 in liver metabolism. Cold Spring Harb. Symp. Quant. Biol. 2011; 76: 139–144. KirS KliewerSA MangelsdorfDJ Roles of FGF19 in liver metabolism Cold Spring Harb. Symp. Quant. Biol. 2011 76 139 144 10.1101/sqb.2011.76.01071021813638 Search in Google Scholar

[15] Lan T, Morgan DA, Rahmouni K, Sonoda J, Fu X, Burgess SC, Holland WL, Kliewer SA, Mangelsdorf DJ. FGF19, FGF21, and an FGFR1/β-Klotho-activating antibody Act on the nervous system to regulate body weight and glycemia. Cell Metab. 2017; 26: 709–718.e3. LanT MorganDA RahmouniK SonodaJ FuX BurgessSC HollandWL KliewerSA MangelsdorfDJ FGF19, FGF21, and an FGFR1/β-Klotho-activating antibody Act on the nervous system to regulate body weight and glycemia Cell Metab. 2017 26 709 718.e3 10.1016/j.cmet.2017.09.005567946828988823 Search in Google Scholar

[16] Morton GJ, Matsen ME, Bracy DP, Meek TH, Nguyen HT, Stefanovski D, Bergman RN, Wasserman DH, Schwartz MW. FGF19 action in the brain induces insulin-independent glucose lowering. J. Clin. Invest. 2013; 123: 4799–4808. MortonGJ MatsenME BracyDP MeekTH NguyenHT StefanovskiD BergmanRN WassermanDH SchwartzMW FGF19 action in the brain induces insulin-independent glucose lowering J. Clin. Invest. 2013 123 4799 4808 10.1172/JCI70710380980024084738 Search in Google Scholar

[17] Gallego-Escuredo JM, Gómez-Ambrosi J, Catalan V, Domingo P, Giralt M, Frühbeck G, Villarroya F. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int. J. Obes. 2015; 39: 121–129. Gallego-EscuredoJM Gómez-AmbrosiJ CatalanV DomingoP GiraltM FrühbeckG VillarroyaF Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients Int. J. Obes. 2015 39 121 129 10.1038/ijo.2014.7624813368 Search in Google Scholar

[18] Johnston IM, Nolan JD, Pattni SS, Appleby RN, Zhang JH, Kennie SL, Madhan GK, Jameie-Oskooei S, Pathmasrirengam S, Lin J, et al. Characterizing factors associated with differences in FGF19 blood levels and synthesis in patients with primary bile acid diarrhea. Am. J. Gastroenterol. 2016; 111: 423–432. JohnstonIM NolanJD PattniSS ApplebyRN ZhangJH KennieSL MadhanGK Jameie-OskooeiS PathmasrirengamS LinJ Characterizing factors associated with differences in FGF19 blood levels and synthesis in patients with primary bile acid diarrhea Am. J. Gastroenterol. 2016 111 423 432 10.1038/ajg.2015.42426856750 Search in Google Scholar

[19] Mráz M, Lacinová Z, Kaválková P, Haluzíková D, Trachta P, Drápalová J, Hanušová V, Haluzík M. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: The influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment. Physiol. Res. 2011; 60: 627–636. MrázM LacinováZ KaválkováP HaluzíkováD TrachtaP DrápalováJ HanušováV HaluzíkM Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: The influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment Physiol. Res. 2011 60 627 636 10.33549/physiolres.93209921574752 Search in Google Scholar

[20] Barutcuoglu B, Basol G, Cakir Y, Cetinkalp S, Parildar Z, Kabaroglu C, Ozmen D, Mutaf I, Bayindir O. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann. Clin. Lab. Sci. 2011; 41: 390–396. BarutcuogluB BasolG CakirY CetinkalpS ParildarZ KabarogluC OzmenD MutafI BayindirO Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome Ann. Clin. Lab. Sci. 2011 41 390 396 Search in Google Scholar

[21] Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology. 2004; 145: 2594–2603. FuL JohnLM AdamsSH YuXX TomlinsonE RenzM WilliamsPM SorianoR CorpuzR MoffatB Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes Endocrinology. 2004 145 2594 2603 10.1210/en.2003-167114976145 Search in Google Scholar

[22] Perry RJ, Lee S, Ma L, Zhang D, Schlessinger J, Shulman GI. FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat. Commun. 2015; 6: 6980. PerryRJ LeeS MaL ZhangD SchlessingerJ ShulmanGI FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis Nat. Commun. 2015 6 6980 10.1038/ncomms7980441350925916467 Search in Google Scholar

[23] Wojcik M, Janus D, Dolezal-Oltarzewska K, Kalicka-Kasperczyk A, Poplawska K, Drozdz D, Sztefko K, Starzyk JB. A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents. J. Pediatr. Endocrinol. Metab. 2012; 25: 1089–1093. WojcikM JanusD Dolezal-OltarzewskaK Kalicka-KasperczykA PoplawskaK DrozdzD SztefkoK StarzykJB A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents J. Pediatr. Endocrinol. Metab. 2012 25 1089 1093 10.1515/jpem-2012-025323329754 Search in Google Scholar

[24] Appleby RN, Moghul I, Khan S, Yee M, Manousou P, Neal DT, Walters JR. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. PLoS. One. 2019; 14: e0211348. ApplebyRN MoghulI KhanS YeeM ManousouP NealDT WaltersJR Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study PLoS. One. 2019 14 e0211348 10.1371/journal.pone.0211348634726230682184 Search in Google Scholar

[25] Friedrich D, Marschall HU, Lammert F. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: A non-randomized controlled pilot trial. BMC Gastroenterol. 2018; 18: 76. FriedrichD MarschallHU LammertF Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: A non-randomized controlled pilot trial BMC Gastroenterol. 2018 18 76 10.1186/s12876-018-0805-z598745729866129 Search in Google Scholar

[26] Hanniman EA, Lambert G, McCarthy TC, Sinal CJ. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 2005; 46: 2595–2604. HannimanEA LambertG McCarthyTC SinalCJ Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice J. Lipid Res. 2005 46 2595 2604 10.1194/jlr.M500390-JLR20016186601 Search in Google Scholar

[27] Alvarez-Sola G, Uriarte I, Latasa MU, Fernandez-Barrena MG, Urtasun R, Elizalde M, Barcena-Varela M, Jiménez M, Chang HC, Barbero R, et al. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis : Development of an FGF19-based chimeric molecule to promote fatty liver regeneration. Gut. 2017; 66: 1818–1828. Alvarez-SolaG UriarteI LatasaMU Fernandez-BarrenaMG UrtasunR ElizaldeM Barcena-VarelaM JiménezM ChangHC BarberoR Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis : Development of an FGF19-based chimeric molecule to promote fatty liver regeneration Gut. 2017 66 1818 1828 10.1136/gutjnl-2016-31297528119353 Search in Google Scholar

[28] Schumacher JD, Guo GL. Pharmacologic modulation of bile acid-FXR-FGF15/FGF19 pathway for the treatment of nonalcoholic steatohepatitis. Handb. Exp. Pharmacol. 2019; 256: 325–357. SchumacherJD GuoGL Pharmacologic modulation of bile acid-FXR-FGF15/FGF19 pathway for the treatment of nonalcoholic steatohepatitis Handb. Exp. Pharmacol. 2019 256 325 357 10.1007/164_2019_228703371331201553 Search in Google Scholar

[29] Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MR, Jaros MJ, Ling L, et al. NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018; 391: 1174–1185. HarrisonSA RinellaME AbdelmalekMF TrotterJF ParedesAH ArnoldHL KugelmasM BashirMR JarosMJ LingL NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Lancet. 2018 391 1174 1185 10.1016/S0140-6736(18)30474-429519502 Search in Google Scholar

[30] Harrison SA, Rossi SJ, Paredes AH, Trotter JF, Bashir MR, Guy CD, Banerjee R, Jaros MJ, Owers S, Baxter BA, et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology. 2020; 71: 1198–1212. HarrisonSA RossiSJ ParedesAH TrotterJF BashirMR GuyCD BanerjeeR JarosMJ OwersS BaxterBA NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis Hepatology. 2020 71 1198 1212 10.1002/hep.30590718743830805949 Search in Google Scholar

[31] Li Z, Lin B, Lin G, Wu Y, Jie Y, Li X, Ko B, Chong Y, Luo J. Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS. One. 2017; 12: e0178580. LiZ LinB LinG WuY JieY LiX KoB ChongY LuoJ Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis PLoS. One. 2017 12 e0178580 10.1371/journal.pone.0178580545355428570655 Search in Google Scholar

[32] Wunsch E, Milkiewicz M, Wasik U, Trottier J, Kempińska-Podhorodecka A, Elias E, Barbier O, Milkiewicz P. Expression of hepatic fibroblast growth factor 19 is enhanced in primary biliary cirrhosis and correlates with severity of the disease. Sci. Rep. 2015; 5: 13462. WunschE MilkiewiczM WasikU TrottierJ Kempińska-PodhorodeckaA EliasE BarbierO MilkiewiczP Expression of hepatic fibroblast growth factor 19 is enhanced in primary biliary cirrhosis and correlates with severity of the disease Sci. Rep. 2015 5 13462 10.1038/srep13462454402126293907 Search in Google Scholar

[33] Luo J, Ko B, Elliott M, Zhou M, Lindhout DA, Phung V, To C, Learned RM, Tian H, DePaoli AM, Ling L. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci. Transl. Med. 2014; 6: 247ra100. LuoJ KoB ElliottM ZhouM LindhoutDA PhungV ToC LearnedRM TianH DePaoliAM LingL A nontumorigenic variant of FGF19 treats cholestatic liver diseases Sci. Transl. Med. 2014 6 247ra100 10.1126/scitranslmed.300909825080475 Search in Google Scholar

[34] Hirschfield GM, Chazouillères O, Drenth JP, Thorburn D, Harrison SA, Landis CS, Mayo MJ, Muir AJ, Trotter JF, Leeming DJ, et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. J. Hepatol. 2019; 70: 483–493. HirschfieldGM ChazouillèresO DrenthJP ThorburnD HarrisonSA LandisCS MayoMJ MuirAJ TrotterJF LeemingDJ Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial J. Hepatol. 2019 70 483 493 10.1016/j.jhep.2018.10.03530414864 Search in Google Scholar

[35] Al-Dury S, Wahlström A, Panzitt K, Thorell A, Ståhlman M, Trauner M, Fickert P, Bäckhed F, Fändriks L, Wagner M, Marschall HU. Obeticholic acid may increase the risk of gallstone formation in susceptible patients. J. Hepatol. 2019; 71: 986–991. Al-DuryS WahlströmA PanzittK ThorellA StåhlmanM TraunerM FickertP BäckhedF FändriksL WagnerM MarschallHU Obeticholic acid may increase the risk of gallstone formation in susceptible patients J. Hepatol. 2019 71 986 991 10.1016/j.jhep.2019.06.01131254596 Search in Google Scholar

[36] Kwak MS, Kim D, Chung GE, Kim W, Kim YJ, Yoon JH. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J. Gastroenterol. 2015; 21: 6287–6295. KwakMS KimD ChungGE KimW KimYJ YoonJH Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population World J. Gastroenterol. 2015 21 6287 6295 10.3748/wjg.v21.i20.6287444510626034364 Search in Google Scholar

[37] Byun S, Jung H, Chen J, Kim YC, Kim DH, Kong B, Guo G, Kemper B, Kemper JK. Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis. J. Biol. Chem. 2019; 294: 8732–8744. ByunS JungH ChenJ KimYC KimDH KongB GuoG KemperB KemperJK Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis J. Biol. Chem. 2019 294 8732 8744 10.1074/jbc.RA119.008360655241930996006 Search in Google Scholar

[38] Zhou M, Learned RM, Rossi SJ, Tian H, DePaoli AM, Ling L. Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis. J. Lipid Res. 2019; 60: 550–565. ZhouM LearnedRM RossiSJ TianH DePaoliAM LingL Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis J. Lipid Res. 2019 60 550 565 10.1194/jlr.M089961639951130679232 Search in Google Scholar

[39] Xu W, Wang Y, Guo Y, Liu J, Ma L, Cao W, Yu B, Zhou Y. Fibroblast growth factor 19 improves cardiac function and mitochondrial energy homoeostasis in the diabetic heart. Biochem. Biophys. Res. Commun. 2018; 505: 242–248. XuW WangY GuoY LiuJ MaL CaoW YuB ZhouY Fibroblast growth factor 19 improves cardiac function and mitochondrial energy homoeostasis in the diabetic heart Biochem. Biophys. Res. Commun. 2018 505 242 248 10.1016/j.bbrc.2018.09.04630243718 Search in Google Scholar

[40] Maeda T, Kanzaki H, Chiba T, Ao J, Kanayama K, Maruta S, Kusakabe Y, Saito T, Kobayashi K, Kiyono S, et al. Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma. BMC Cancer. 2019; 19: 1088. MaedaT KanzakiH ChibaT AoJ KanayamaK MarutaS KusakabeY SaitoT KobayashiK KiyonoS Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma BMC Cancer. 2019 19 1088 10.1186/s12885-019-6322-9684928231718608 Search in Google Scholar

[41] Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, et al. First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov. 2019; 9: 1696–1707. KimRD SarkerD MeyerT YauT MacarullaT ParkJW ChooSP HollebecqueA SungMW LimHY First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma Cancer Discov. 2019 9 1696 1707 10.1158/2159-8290.CD-19-055531575541 Search in Google Scholar

[42] Raja A, Park I, Haq F, Ahn SM. FGF19-FGFR4 signaling in hepatocellular carcinoma. Cells. 2019; 8: 536. RajaA ParkI HaqF AhnSM FGF19-FGFR4 signaling in hepatocellular carcinoma Cells. 2019 8 536 10.3390/cells8060536662712331167419 Search in Google Scholar

[43] Teng Y, Zhao H, Gao L, Zhang W, Shull AY, Shay C. FGF19 protects hepatocellular carcinoma cells against endoplasmic reticulum stress via activation of FGFR4-GSK3β-Nrf2 signaling. BMC Cancer Res. 2017; 77: 6215–6225. TengY ZhaoH GaoL ZhangW ShullAY ShayC FGF19 protects hepatocellular carcinoma cells against endoplasmic reticulum stress via activation of FGFR4-GSK3β-Nrf2 signaling BMC Cancer Res. 2017 77 6215 6225 10.1158/0008-5472.CAN-17-203928951455 Search in Google Scholar

[44] Xu YF, Yang XQ, Lu XF, Guo S, Liu Y, Iqbal M, Ning SL, Yang H, Suo N, Chen YX. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. Biochem. Biophys. Res. Commun. 2014; 446: 54–60. XuYF YangXQ LuXF GuoS LiuY IqbalM NingSL YangH SuoN ChenYX Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma Biochem. Biophys. Res. Commun. 2014 446 54 60 10.1016/j.bbrc.2014.02.05024565842 Search in Google Scholar

[45] Wang D, Zhang J, Li Z, Han J, Gao Y, Chen M, Li Y. Upregulation of fibroblast growth factor 19 is associated with the initiation of colorectal adenoma. Dig. Dis. 2019; 37: 214–225. WangD ZhangJ LiZ HanJ GaoY ChenM LiY Upregulation of fibroblast growth factor 19 is associated with the initiation of colorectal adenoma Dig. Dis. 2019 37 214 225 10.1159/00049445430517925 Search in Google Scholar

[46] Li F, Li Z, Han Q, Cheng Y, Ji W, Yang Y, Lu S, Xia W. Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104. Oncogene. 2020; 39: 3507–3521. LiF LiZ HanQ ChengY JiW YangY LuS XiaW Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104 Oncogene. 2020 39 3507 3521 10.1038/s41388-020-1227-2717658632111983 Search in Google Scholar

[47] Nolan JD, Johnston IM, Pattni SS, Dew T, Orchard TR, Walters JR. Diarrhea in Crohn’s disease: Investigating the role of the ileal hormone fibroblast growth factor 19. J. Crohns Colitis. 2015; 9: 125–131. NolanJD JohnstonIM PattniSS DewT OrchardTR WaltersJR Diarrhea in Crohn’s disease: Investigating the role of the ileal hormone fibroblast growth factor 19 J. Crohns Colitis. 2015 9 125 131 10.1093/ecco-jcc/jju02225518063 Search in Google Scholar

[48] Tiratterra E, Franco P, Porru E, Katsanos K, Christodoulou DK, Roda G. Role of bile acids in inflammatory bowel disease. Ann. Gastroenterol. 2018; 31: 266–272. TiratterraE FrancoP PorruE KatsanosK ChristodoulouDK RodaG Role of bile acids in inflammatory bowel disease Ann. Gastroenterol. 2018 31 266 272 10.20524/aog.2018.0239592484829720851 Search in Google Scholar

[49] Panek-Jeziorna M, Mulak A. An inverse correlation of serum fibroblast growth factor 19 with abdominal pain and inflammatory markers in patients with ulcerative colitis. Gastroenterol. Res. Pract. 2020; 2020: 2389312. Panek-JeziornaM MulakA An inverse correlation of serum fibroblast growth factor 19 with abdominal pain and inflammatory markers in patients with ulcerative colitis Gastroenterol. Res. Pract. 2020 2020 2389312 Search in Google Scholar

[50] Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011; 60: 463–472. GadaletaRM van ErpecumKJ OldenburgB WillemsenEC RenooijW MurzilliS KlompLW SiersemaPD SchipperME DaneseS Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease Gut. 2011 60 463 472 10.1136/gut.2010.21215921242261 Search in Google Scholar

[51] Reiche M, Bachmann A, Lössner U, Blüher M, Stumvoll M, Fasshauer M. Fibroblast growth factor 19 serum levels: Relation to renal function and metabolic parameters. Horm. Metab. Res. 2010; 42: 178–181. ReicheM BachmannA LössnerU BlüherM StumvollM FasshauerM Fibroblast growth factor 19 serum levels: Relation to renal function and metabolic parameters Horm. Metab. Res. 2010 42 178 181 10.1055/s-0029-124324920013647 Search in Google Scholar

[52] Marchelek-Myśliwiec M, Dziedziejko V, Nowosiad-Magda M, Dołęgowska K, Dołęgowska B, Pawlik A, Safranow K, Wiśniewska M, Stępniewska J, Domański M, Ciechanowski K: Chronic kidney disease is associated with increased plasma levels of fibroblast growth factors 19 and 21. Kidney Blood Press Res. 2019; 44: 1207–1218. Marchelek-MyśliwiecM DziedziejkoV Nowosiad-MagdaM DołęgowskaK DołęgowskaB PawlikA SafranowK WiśniewskaM StępniewskaJ DomańskiM CiechanowskiK Chronic kidney disease is associated with increased plasma levels of fibroblast growth factors 19 and 21 Kidney Blood Press Res. 2019 44 1207 1218 10.1159/00050264731614355 Search in Google Scholar

[53] Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta. 2000; 1492: 203–206. NishimuraT NakatakeY KonishiM ItohN Identification of a novel FGF, FGF-21, preferentially expressed in the liver Biochim. Biophys. Acta. 2000 1492 203 206 10.1016/S0167-4781(00)00067-110858549 Search in Google Scholar

[54] Dolegowska K, Marchelek-Mysliwiec M, Nowosiad-Magda M, Slawinski M, Dolegowska B. FGF19 subfamily members : FGF19 and FGF21. J. Physiol. Biochem. 2019; 75: 229–240. DolegowskaK Marchelek-MysliwiecM Nowosiad-MagdaM SlawinskiM DolegowskaB FGF19 subfamily members : FGF19 and FGF21 J. Physiol. Biochem. 2019 75 229 240 10.1007/s13105-019-00675-7661174930927227 Search in Google Scholar

[55] Martínez-Garza Ú, Torres-Oteros D, Yarritu-Gallego A, Marrero PF, Haro D, Relat J. Fibroblast growth factor 21 and the adaptive response to nutritional challenges. Int. J. Mol. Sci. 2019; 20: 4692. Martínez-GarzaÚ Torres-OterosD Yarritu-GallegoA MarreroPF HaroD RelatJ Fibroblast growth factor 21 and the adaptive response to nutritional challenges Int. J. Mol. Sci. 2019 20 4692 10.3390/ijms20194692680167031546675 Search in Google Scholar

[56] Ong KL, Rye KA, O’Connell R, Jenkins AJ, Brown C, Xu A, Sullivan DR, Barter PJ, Keech A.C., FIELD study investigators: Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 2012; 97: 4701–4708. OngKL RyeKA O’ConnellR JenkinsAJ BrownC XuA SullivanDR BarterPJ KeechA.C. FIELD study investigators Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes J. Clin. Endocrinol. Metab. 2012 97 4701 4708 10.1210/jc.2012-226723144467 Search in Google Scholar

[57] Cuevas-Ramos D, Mehta R, Aguilar-Salinas CA. Fibroblast growth factor 21 and browning of white adipose tissue. Front Physiol. 2019; 10: 37. Cuevas-RamosD MehtaR Aguilar-SalinasCA Fibroblast growth factor 21 and browning of white adipose tissue Front Physiol. 2019 10 37 10.3389/fphys.2019.00037637073730804796 Search in Google Scholar

[58] Hernandez G, Luo T, Javed TA, Wen L, Kalwat MA, Vale K, Ammouri F, Husain SZ, Kliewer SA, Mangelsdorf DJ. Pancreatitis is an FGF21-deficient state that is corrected by replacement therapy. Sci. Transl. Med. 2020; 12: eaay5186. HernandezG LuoT JavedTA WenL KalwatMA ValeK AmmouriF HusainSZ KliewerSA MangelsdorfDJ Pancreatitis is an FGF21-deficient state that is corrected by replacement therapy Sci. Transl. Med. 2020 12 eaay5186 10.1126/scitranslmed.aay5186703498131915301 Search in Google Scholar

[59] BonDurant LD, Potthoff MJ. Fibroblast growth factor 21: A versatile regulator of metabolic homeostasis. Annu. Rev. Nutr. 2018; 38: 173–196. BonDurantLD PotthoffMJ Fibroblast growth factor 21: A versatile regulator of metabolic homeostasis Annu. Rev. Nutr. 2018 38 173 196 10.1146/annurev-nutr-071816-064800696425829727594 Search in Google Scholar

[60] Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R, Mohammadi M, Finck BN, Mangelsdorf DJ, Kliewer SA, Burgess SC. FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl. Acad. Sci. USA. 2009; 106: 10853–10858. PotthoffMJ InagakiT SatapatiS DingX HeT GoetzR MohammadiM FinckBN MangelsdorfDJ KliewerSA BurgessSC FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response Proc. Natl. Acad. Sci. USA. 2009 106 10853 10858 10.1073/pnas.0904187106270561319541642 Search in Google Scholar

[61] Zhang Y, Xie Y, Berglund ED, Coate KC, He TT, Katafuchi T, Xiao G, Potthoff MJ, Wei W, Wan Y. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. Elife. 2012; 1: e00065. ZhangY XieY BerglundED CoateKC HeTT KatafuchiT XiaoG PotthoffMJ WeiW WanY The starvation hormone, fibroblast growth factor-21, extends lifespan in mice Elife. 2012 1 e00065 10.7554/eLife.00065346659123066506 Search in Google Scholar

[62] Morrice N, Mcilroy GD, Tammireddy SR, Reekie J, Shearer KD, Doherty MK, Delibegović M, Whitfield PD, Mody N. Elevated fibroblast growth factor 21 (FGF21) in obese, insulin resistant states is normalised by the synthetic retinoid fenretinide in mice. Sci. Rep. 2017; 7: 43782. MorriceN McilroyGD TammireddySR ReekieJ ShearerKD DohertyMK DelibegovićM WhitfieldPD ModyN Elevated fibroblast growth factor 21 (FGF21) in obese, insulin resistant states is normalised by the synthetic retinoid fenretinide in mice Sci. Rep. 2017 7 43782 10.1038/srep43782533566328256636 Search in Google Scholar

[63] Jimenez V, Jambrina C, Casana E, Sacristan V, Muñoz S, Darriba S, Rodó J, Mallol C, Garcia M, León X, et al. FGF 21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol. Med. 2018; 10: e8791. JimenezV JambrinaC CasanaE SacristanV MuñozS DarribaS RodóJ MallolC GarciaM LeónX FGF 21 gene therapy as treatment for obesity and insulin resistance EMBO Mol. Med. 2018 10 e8791 10.15252/emmm.201708791607953329987000 Search in Google Scholar

[64] Kruse R, Vienberg SG, Vind BF, Andersen B, Højlund K. Effects of insulin and exercise training on FGF21, its receptors and target genes in obesity and type 2 diabetes. Diabetologia. 2017; 60: 2042–2051. KruseR VienbergSG VindBF AndersenB HøjlundK Effects of insulin and exercise training on FGF21, its receptors and target genes in obesity and type 2 diabetes Diabetologia. 2017 60 2042 2051 10.1007/s00125-017-4373-528721439 Search in Google Scholar

[65] Zhang J, Weng W, Wang K, Lu X, Cai L, Sun J. The role of FGF21 in type 1 diabetes and its complications. Int. J. Biol. Sci. 2018; 14: 1000–1011. ZhangJ WengW WangK LuX CaiL SunJ The role of FGF21 in type 1 diabetes and its complications Int. J. Biol. Sci. 2018 14 1000 1011 10.7150/ijbs.25026603673529989062 Search in Google Scholar

[66] Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK, Moller DE. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013; 18: 333–340. GaichG ChienJY FuH GlassLC DeegMA HollandWL KharitonenkovA BumolT SchilskeHK MollerDE The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes Cell Metab. 2013 18 333 340 10.1016/j.cmet.2013.08.00524011069 Search in Google Scholar

[67] Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M, Lu Z, Gao M, Bao Y, Jia W. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc. Diabetol. 2013; 12: 124. ShenY MaX ZhouJ PanX HaoY ZhouM LuZ GaoM BaoY JiaW Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease Cardiovasc. Diabetol. 2013 12 124 10.1186/1475-2840-12-124376615023981342 Search in Google Scholar

[68] Rusli F, Deelen J, Andriyani E, Boekschoten MV, Lute C, van den Akker EB, Müller M, Beekman M, Steegenga WT. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice. Sci. Rep. 2016; 6: 30484. RusliF DeelenJ AndriyaniE BoekschotenMV LuteC van den AkkerEB MüllerM BeekmanM SteegengaWT Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice Sci. Rep. 2016 6 30484 10.1038/srep30484496576127470139 Search in Google Scholar

[69] Tucker B, Li H, Long X, Rye KA, Ong KL. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metabolism. 2019; 101: 153994. TuckerB LiH LongX RyeKA OngKL Fibroblast growth factor 21 in non-alcoholic fatty liver disease Metabolism. 2019 101 153994 10.1016/j.metabol.2019.15399431672443 Search in Google Scholar

[70] Waluga M, Kukla M, Zorniak M, Kajor M, Liszka L, Dyaczynski M, Kowalski G, Zadlo D, Waluga E, Olczyk P, et al. Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease. J. Physiol. Pharmacol. 2017; 68: 363–374. WalugaM KuklaM ZorniakM KajorM LiszkaL DyaczynskiM KowalskiG ZadloD WalugaE OlczykP Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease J. Physiol. Pharmacol. 2017 68 363 374 Search in Google Scholar

[71] Yang M, Xu D, Liu Y, Guo X, Li W, Guo C, Zhang H, Gao Y, Mao Y, Zhao J. Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis. PLoS. One. 2015; 10: e0131664. YangM XuD LiuY GuoX LiW GuoC ZhangH GaoY MaoY ZhaoJ Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis PLoS. One. 2015 10 e0131664 10.1371/journal.pone.0131664448672926121037 Search in Google Scholar

[72] Huang Z, Xu A, Cheung BMY. The potential role of fibroblast growth factor 21 in lipid metabolism and hypertension. Curr. Hypertens. Rep. 2017; 19: 28. HuangZ XuA CheungBMY The potential role of fibroblast growth factor 21 in lipid metabolism and hypertension Curr. Hypertens. Rep. 2017 19 28 10.1007/s11906-017-0730-528337713 Search in Google Scholar

[73] Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007; 5: 426–437. BadmanMK PissiosP KennedyAR KoukosG FlierJS Maratos-FlierE Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states Cell Metab. 2007 5 426 437 10.1016/j.cmet.2007.05.00217550778 Search in Google Scholar

[74] Sanyal A, Charles ED, Neuschwander-Tetri BA, Loomba R, Harrison SA, Abdelmalek MF, Lawitz EJ, Halegoua-DeMarzio D, Kundu S, Noviello S, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 2018; 392: 2705–2717. SanyalA CharlesED Neuschwander-TetriBA LoombaR HarrisonSA AbdelmalekMF LawitzEJ Halegoua-DeMarzioD KunduS NovielloS Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 2a trial Lancet. 2018 392 2705 2717 10.1016/S0140-6736(18)31785-930554783 Search in Google Scholar

[75] Yan X, Gou Z, Li Y, Wang Y, Zhu J, Xu G, Zhang Q. Fibroblast growth factor 21 inhibits atherosclerosis in apoE^−/− mice by ameliorating Fas-mediated apoptosis. Lipids Health Dis. 2018; 17: 203. YanX GouZ LiY WangY ZhuJ XuG ZhangQ Fibroblast growth factor 21 inhibits atherosclerosis in apoE^−/− mice by ameliorating Fas-mediated apoptosis Lipids Health Dis. 2018 17 203 10.1186/s12944-018-0846-x611450230157856 Search in Google Scholar

[76] Tabari FS, Karimian A, Parsian H, Rameshknia V, Mahmoodpour A, Majidinia M, Maniati M, Yousefi B. The roles of FGF21 in atherosclerosis pathogenesis. Rev. Endocr. Metab. Disord. 2019; 20: 103–114. TabariFS KarimianA ParsianH RameshkniaV MahmoodpourA MajidiniaM ManiatiM YousefiB The roles of FGF21 in atherosclerosis pathogenesis Rev. Endocr. Metab. Disord. 2019 20 103 114 10.1007/s11154-019-09488-x30879171 Search in Google Scholar

[77] Liu L, Zhao C, Yang Y, Kong X, Shao T, Ren L, Zhuang X, Yin B, Dryden G, Mcclain C, et al. Fibroblast growth factor 21 deficiency attenuates experimental colitis-induced adipose tissue lipolysis. Gastroenterol. Res. Pract. 2017; 2017: 3089378. LiuL ZhaoC YangY KongX ShaoT RenL ZhuangX YinB DrydenG McclainC Fibroblast growth factor 21 deficiency attenuates experimental colitis-induced adipose tissue lipolysis Gastroenterol. Res. Pract. 2017 2017 3089378 10.1155/2017/3089378544403728584524 Search in Google Scholar

[78] Tomasik PJ, Pieczarkowski SH, Fyderek K, Sztefko K. Fgf-21 in inflammatory bowel diseases. Pediatr. Res. 2010; 68: 523. TomasikPJ PieczarkowskiSH FyderekK SztefkoK Fgf-21 in inflammatory bowel diseases Pediatr. Res. 2010 68 523 10.1203/00006450-201011001-01052 Search in Google Scholar

[79] Feingold KR, Grunfeld C, Heuer JG, Gupta A, Cramer M, Zhang T, Shigenaga JK, Patzek SM, Chan ZW, Moser A, et al. FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis. Endocrinology. 2012; 153: 2689–2700. FeingoldKR GrunfeldC HeuerJG GuptaA CramerM ZhangT ShigenagaJK PatzekSM ChanZW MoserA FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis Endocrinology. 2012 153 2689 2700 10.1210/en.2011-1496335961322474187 Search in Google Scholar

[80] Hindricks J, Ebert T, Bachmann A, Kralisch S, Lössner U, Kratzsch J, Stolzenburg JU, Dietel A, Beige J, Anders M, et al. Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clin. Endocrinol. 2014; 80: 918–924. HindricksJ EbertT BachmannA KralischS LössnerU KratzschJ StolzenburgJU DietelA BeigeJ AndersM Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction Clin. Endocrinol. 2014 80 918 924 10.1111/cen.1238024612017 Search in Google Scholar

[81] Kuro-O M. Klotho and endocrine fibroblast growth factors: Markers of chronic kidney disease progression and cardiovascular complications? Nephrol. Dial. Transplant. 2019; 34: 15–21. Kuro-OM Klotho and endocrine fibroblast growth factors: Markers of chronic kidney disease progression and cardiovascular complications? Nephrol. Dial. Transplant. 2019 34 15 21 10.1093/ndt/gfy12629800324 Search in Google Scholar

[82] Kohara M, Masuda T, Shiizaki K, Akimoto T, Watanabe Y, Honma S, Sekiguchi C, Miyazawa Y, Kusano E, Kanda Y, et al. Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease. PLoS. One. 2017; 12: e0178971. KoharaM MasudaT ShiizakiK AkimotoT WatanabeY HonmaS SekiguchiC MiyazawaY KusanoE KandaY Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease PLoS. One. 2017 12 e0178971 10.1371/journal.pone.0178971545946428582462 Search in Google Scholar

[83] Chang HH, Chen PS, Cheng YW, Wang TY, Yang YK, Lu RB. FGF21 is associated with metabolic effects and treatment response in depressed bipolar II disorder patients treated with valproate. Int. J. Neuropsychopharmacol. 2018; 21: 319–324. ChangHH ChenPS ChengYW WangTY YangYK LuRB FGF21 is associated with metabolic effects and treatment response in depressed bipolar II disorder patients treated with valproate Int. J. Neuropsychopharmacol. 2018 21 319 324 10.1093/ijnp/pyx093588847029618013 Search in Google Scholar

[84] Liu Y, Wang M, Tan X, Wang X, Yang X, Xiao J, Li X, Wang F. Negative correlation between cerebrospinal fluid FGF21 levels and BDI scores in male Chinese subjects. Psychiatry Res. 2017; 252: 111–113. LiuY WangM TanX WangX YangX XiaoJ LiX WangF Negative correlation between cerebrospinal fluid FGF21 levels and BDI scores in male Chinese subjects Psychiatry Res. 2017 252 111 113 10.1016/j.psychres.2017.01.07528259034 Search in Google Scholar

[85] Wang X, Zhu L, Hu J, Guo R, Ye S, Liu F, Wang D, Zhao Y, Hu A, Wang X, et al. FGF21 attenuated LPS-induced depressive-like behavior via inhibiting the inflammatory pathway. Front Pharmacol. 2020; 11: 154. WangX ZhuL HuJ GuoR YeS LiuF WangD ZhaoY HuA WangX FGF21 attenuated LPS-induced depressive-like behavior via inhibiting the inflammatory pathway Front Pharmacol. 2020 11 154 10.3389/fphar.2020.00154705879732184729 Search in Google Scholar

[86] Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 2000; 277: 494–498. YamashitaT YoshiokaM ItohN Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain Biochem. Biophys. Res. Commun. 2000 277 494 498 10.1006/bbrc.2000.369611032749 Search in Google Scholar

[87] Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol. Rev. 2012; 92: 131–155. MartinA DavidV QuarlesLD Regulation and function of the FGF23/klotho endocrine pathways Physiol. Rev. 2012 92 131 155 10.1152/physrev.00002.2011330626522298654 Search in Google Scholar

[88] David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, Zumbrennen-Bullough KB, Sun CC, Lin HY, Babitt JL, Wolf M. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016; 89: 135–146. DavidV MartinA IsakovaT SpauldingC QiL RamirezV Zumbrennen-BulloughKB SunCC LinHY BabittJL WolfM Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production Kidney Int. 2016 89 135 146 10.1038/ki.2015.290485481026535997 Search in Google Scholar

[89] Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am. J. Physiol. Renal Physiol. 2010; 299: F882–F889. Lavi-MoshayoffV WassermanG MeirT SilverJ Naveh-ManyT PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop Am. J. Physiol. Renal Physiol. 2010 299 F882 F889 10.1152/ajprenal.00360.201020685823 Search in Google Scholar

[90] Courbebaisse M, Lanske B. Biology of fibroblast growth factor 23: From physiology to pathology. Cold Spring Harb. Perspect. Med. 2018; 8: a031260. CourbebaisseM LanskeB Biology of fibroblast growth factor 23: From physiology to pathology Cold Spring Harb. Perspect. Med. 2018 8 a031260 10.1101/cshperspect.a031260593257428778965 Search in Google Scholar

[91] Czaya B, Faul C. The role of fibroblast growth factor 23 in inflammation and anemia. Int. J. Mol. Sci. 2019; 20: 4195. CzayaB FaulC The role of fibroblast growth factor 23 in inflammation and anemia Int. J. Mol. Sci. 2019 20 4195 10.3390/ijms20174195674752231461904 Search in Google Scholar

[92] Francis C, David V. Inflammation regulates fibroblast growth factor 23 production. Curr. Opin. Nephrol. Hypertens. 2016; 25: 325–332. FrancisC DavidV Inflammation regulates fibroblast growth factor 23 production Curr. Opin. Nephrol. Hypertens. 2016 25 325 332 10.1097/MNH.0000000000000232501660827191351 Search in Google Scholar

[93] Zhang B, Umbach AT, Chen H, Yan J, Fakhri H, Fajol A, Salker MS, Spichtig D, Daryadel A, Wagner CA, Michael F. Up-regulation of FGF23 release by aldosterone. Biochem. Biophys. Res. Commun. 2016; 470: 384–390. ZhangB UmbachAT ChenH YanJ FakhriH FajolA SalkerMS SpichtigD DaryadelA WagnerCA MichaelF Up-regulation of FGF23 release by aldosterone Biochem. Biophys. Res. Commun. 2016 470 384 390 10.1016/j.bbrc.2016.01.03426773502 Search in Google Scholar

[94] Bär L, Feger M, Fajol A, Klotz LO, Zeng S, Lang F, Hocher B, Föller M. Insulin suppresses the production of fibroblast growth factor 23 (FGF23). Proc. Natl. Acad. Sci. USA. 2018; 115: 5804–5809. BärL FegerM FajolA KlotzLO ZengS LangF HocherB FöllerM Insulin suppresses the production of fibroblast growth factor 23 (FGF23) Proc. Natl. Acad. Sci. USA. 2018 115 5804 5809 10.1073/pnas.1800160115598451429760049 Search in Google Scholar

[95] Toro L, Barrientos V, León P, Rojas M, Gonzalez M, González-Ibáñez A, Illanes S, Sugikawa K, Abarzúa N, Bascuñán C, et al. Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury. Kidney Int. 2018; 93: 1131–1141. ToroL BarrientosV LeónP RojasM GonzalezM González-IbáñezA IllanesS SugikawaK AbarzúaN BascuñánC Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury Kidney Int. 2018 93 1131 1141 10.1016/j.kint.2017.11.01829395333 Search in Google Scholar

[96] Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 2004; 113: 561–568. ShimadaT KakitaniM YamazakiY HasegawaH TakeuchiY FujitaT FukumotoS TomizukaK YamashitaT Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism J. Clin. Invest. 2004 113 561 568 10.1172/JCI200419081 Search in Google Scholar

[97] Bai X, Miao D, Li J, Goltzman D, Karaplis AC: Transgenic mice over-expressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology. 2004; 145: 5269–5279. BaiX MiaoD LiJ GoltzmanD KaraplisAC Transgenic mice over-expressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders Endocrinology. 2004 145 5269 5279 10.1210/en.2004-023315284207 Search in Google Scholar

[98] Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, Pohl EE, Erben RG. FGF 23 regulates renal sodium handling and blood pressure. EMBO Mol. Med. 2014; 6: 744–759. AndrukhovaO SlavicS SmorodchenkoA ZeitzU ShalhoubV LanskeB PohlEE ErbenRG FGF 23 regulates renal sodium handling and blood pressure EMBO Mol. Med. 2014 6 744 759 10.1002/emmm.201303716420335324797667 Search in Google Scholar

[99] Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi MS, Naveh-Many TS, Silver J. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 2007; 117: 4003–4008. Ben-DovIZ GalitzerH Lavi-MoshayoffV GoetzR Kuro-oM MohammadiMS Naveh-ManyTS SilverJ The parathyroid is a target organ for FGF23 in rats J. Clin. Invest. 2007 117 4003 4008 10.1172/JCI32409206619617992255 Search in Google Scholar

[100] Olauson H, Lindberg K, Amin R, Sato T, Jia T, Goetz R, Mohammadi M, Andersson G, Lanske B, Larsson TE. Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS. Genet. 2013; 9: e1003975. OlausonH LindbergK AminR SatoT JiaT GoetzR MohammadiM AnderssonG LanskeB LarssonTE Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion PLoS. Genet. 2013 9 e1003975 10.1371/journal.pgen.1003975386104024348262 Search in Google Scholar

[101] Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79: 1370–1378. IsakovaT WahlP VargasGS GutiérrezOM SciallaJ XieH ApplebyD NesselL BellovichK ChenJ Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease Kidney Int. 2011 79 1370 1378 10.1038/ki.2011.47313439321389978 Search in Google Scholar

[102] Bai Z, Fang F, Xu Z, Lu C, Wang X, Chen J, Pan J, Wang J, Li Y. Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill children. BMC Pediatr. 2018; 18: 192. BaiZ FangF XuZ LuC WangX ChenJ PanJ WangJ LiY Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill children BMC Pediatr. 2018 18 192 10.1186/s12887-018-1175-y600409129907141 Search in Google Scholar

[103] Vervloet M. Renal and extrarenal effects of fibroblast growth factor 23. Nat. Rev. Nephrol. 2019; 15: 109–120. VervloetM Renal and extrarenal effects of fibroblast growth factor 23 Nat. Rev. Nephrol. 2019 15 109 120 10.1038/s41581-018-0087-230514976 Search in Google Scholar

[104] Durlacher-Betzer K, Hassan A, Levi R, Axelrod J, Silver J, Naveh-Many T. Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. Kidney Int. 2018; 94: 315–325. Durlacher-BetzerK HassanA LeviR AxelrodJ SilverJ Naveh-ManyT Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease Kidney Int. 2018 94 315 325 10.1016/j.kint.2018.02.02629861060 Search in Google Scholar

[105] Prié D, Ravery V, Boccon-Gibod L, Friedlander G. Frequency of renal phosphate leak among patients with calcium nephrolithiasis. Kidney Int. 2001; 60: 272–276. PriéD RaveryV Boccon-GibodL FriedlanderG Frequency of renal phosphate leak among patients with calcium nephrolithiasis Kidney Int. 2001 60 272 276 10.1046/j.1523-1755.2001.00796.x11422761 Search in Google Scholar

[106] Rendina D, Mossetti G, De Filippo G, Cioffi M, Strazzullo P. Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak. J. Clin. Endocrinol. Metab. 2006; 91: 959–963. RendinaD MossettiG De FilippoG CioffiM StrazzulloP Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak J. Clin. Endocrinol. Metab. 2006 91 959 963 10.1210/jc.2005-160616352682 Search in Google Scholar

[107] Balani S, Perwad F. Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2020; 29: 531–536. BalaniS PerwadF Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease Curr. Opin. Nephrol. Hypertens. 2020 29 531 536 10.1097/MNH.000000000000063132701599 Search in Google Scholar

[108] El-Hodhod MA, Hamdy AM, Abbas AA, Moftah SG, Ramadan AA. Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease. BMC Gastroenterol. 2012; 12: 44. El-HodhodMA HamdyAM AbbasAA MoftahSG RamadanAA Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease BMC Gastroenterol. 2012 12 44 10.1186/1471-230X-12-44343806722551310 Search in Google Scholar

[109] Jimenez KM, Gasche C. Management of iron deficiency anaemia in inflammatory bowel disease. Acta Haematol. 2019; 142: 30–36. JimenezKM GascheC Management of iron deficiency anaemia in inflammatory bowel disease Acta Haematol. 2019 142 30 36 10.1159/00049672830970351 Search in Google Scholar

[110] Oikonomou KA, Orfanidou TI, Vlychou MK, Kapsoritakis AN, Tsezou A, Malizos KN, Potamianos SP. Lower fibroblast growth factor 23 levels in young adults with Crohn disease as a possible secondary compensatory effect on the disturbance of bone and mineral metabolism. J. Clin. Densitom. 2014; 17: 177–184. OikonomouKA OrfanidouTI VlychouMK KapsoritakisAN TsezouA MalizosKN PotamianosSP Lower fibroblast growth factor 23 levels in young adults with Crohn disease as a possible secondary compensatory effect on the disturbance of bone and mineral metabolism J. Clin. Densitom. 2014 17 177 184 10.1016/j.jocd.2013.03.01923623649 Search in Google Scholar

[111] López-Muñoz P, Beltrán B, Sáez-González E, Alba A, Nos P, Iborra M. Influence of vitamin D deficiency on inflammatory markers and clinical disease activity in IBD patients. Nutrients. 2019; 11: 1059. López-MuñozP BeltránB Sáez-GonzálezE AlbaA NosP IborraM Influence of vitamin D deficiency on inflammatory markers and clinical disease activity in IBD patients Nutrients. 2019 11 1059 10.3390/nu11051059656786631083541 Search in Google Scholar